apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain

Journal of Clinical Investigation

Volumn 118, Issue 12, 2008, Pages 4002-4013

  Deane, Rashid ^a   Sagare, Abhay ^a   Hamm, Katie ^a   Parisi, Margaret ^a   Lane, Steven ^a   Finn, Mary Beth ^b   Holtzman, David M ^b   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ISOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMPLEX FORMATION; CONTROLLED STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ASTROCYTES; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PROTEIN ISOFORMS; RECEPTORS, LDL; TUMOR SUPPRESSOR PROTEINS;

EID: 57449084208     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36663     Document Type: Article

References (67)

1. Iadecola, C. 2004. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5:347-360.
2. Zlokovic, B.V. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57:178-201.
3. Rovelet-Lecrux, A., et al. 2006. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38:24-26.
4. Hardy, J. 2006. A hundred years of Alzheimer's disease research. Neuron. 52:3-13.
5. Deane, R., Sagare, A., and Zlokovic, B.V. 2008. The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer's disease. Curr. Pharm. Des. 14:1601-1605.
6. Lee, V.M.Y., Balin, B.J., Otvos, L., Jr., and Trojanowski, J.Q. 1991. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science. 251:675-678.
7. SantaCruz, K., et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 309:476-481.
8. Tanzi, R.E. 2005. The synaptic Abeta hypothesis of Alzheimer disease. Nat. Neurosci. 8:977-979.
9. Snyder, E.M., et al. 2005. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8:1051-1058.
10. Selkoe, D.J. 2001. Clearing the brain's amyloid cobwebs. Neuron. 32:177-180.
11. Holtzman, D.M., and Zlokovic, B.V. 2007. Role of Aβ transport and clearance in the pathogenesis and treatment of Alzheimer's disease. In Alzheimer's disease: advances in genetics, molecular and cellular biology. S. Sisodia, and R.E. Tanzi, editors. Springer. New York, New York, USA. 179-198.
12. Haass, C., and Selkoe, D.J. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8:101-112.
13. Zlokovic, B.V., Yamada, Y., Holtzman, D.M., Ghiso, J., and Frangione, B. 2000. Clearance of amyloid β-peptide from brain: transport or metabolism? Nat. Med. 6:718-719.
14. Tanzi, R.E., Moir, R.D., and Wagner, S.L. 2004. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron. 43:605-608.
15. Zlokovic, B.V. 2008. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics. 5:409-414.
16. Shibata, M., et al. 2000. Clearance of Alzheimer's amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489-1499.
17. Deane, R., et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333-344.
18. Cirrito, J.R., et al. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115:3285-3290.
19. Bell, R.D., et al. 2007. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27:909-918.
20. Nazer, B., Hong, S., and Selkoe, D.J. 2008. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 30:94-102.
21. Holtzman, D.M. 2004. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J. Mol. Neurosci. 23:247-254.
22. Holtzman, D.M., et al. 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97:2892-2897.
23. DeMattos, R.B., et al. 2004. ApoE and clusterin cooperatively suppress Aβ levels and deposition: Evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron. 41:193-202.
24. Zlokovic, B.V. 2005. Neurovascular mechanisms of Alzheimer's neurodegeneration Trends Neurosci. 28:202-208.
25. Jiang, Q., et al. 2008. ApoE promotes the proteolytic degradation of Aβ. Neuron. 58:681-693.
26. Bales, K.R., et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17:263-264.
27. Holtzman, D.M., et al. 1999. Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103:R15-R21.
28. Fagan, A.M., et al. 2002. Human and murine apoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:305-318.
29. Fryer, J.D., et al. 2003. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23:7889-7896.
30. Fryer, J.D., et al. 2005. Human apolipoprotein E4 alters the amyloid-β 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25:2803-2810.
31. Xu, F., et al. 2008. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J. Neurosci. 28:5312-5320.
32. Li, Y., Lu, W., Marzolo, M.P., and Bu, G. 2001. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J. Biol. Chem. 276:18000-18006.
33. Morikawa, M., et al. 2005. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β. Neurobiol. Dis. 19:66-76.
34. Deane, R., et al. 2005. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25:11495-11503.
35. May, P., Herz, J., and Bock, H.H. 2005. Molecular mechanisms of lipoprotein receptor signalling. Cell. Mol. Life Sci. 62:2325-2338.
36. Zlokovic, B.V., Deane, R., Sallstrom, J., Chow, N., and Miano, J.M. 2005. Neurovascular pathways and Alzheimer amyloid β-peptide. Brain Pathol. 15:78-83.
37. Martel, C.L., et al. 1997. Isoform-specific effects of apolipoproteins E2, E3 and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J. Neurochem. 69:1995-2004.
38. Roses, A.D. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47:387-400.
39. Bertram, L., and Tanzi, R.E. 2005. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115:1449-1457.
40. Herz, J., and Hui, D.Y. 2004. Lipoprotein receptors in the vascular wall. Curr. Opin. Lipidol. 15:175-181.
41. Zlokovic, B.V., et al. 1996. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid beta at the bloodbrain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U. S. A. 93:4229-4234.
42. Dehouck, B., et al. 1997. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138:877-889.
43. Kreuter, J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47:65-81.
44. Linton, M.F., et al. 1991. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88:270-281.
45. Wahrle, S.E., and Holtzman, D.M. 2003. Differential metabolism of ApoE isoforms in plasma and CSF. Exp. Neurol. 183:4-6.
46. Ruiz, J., et al. 2005. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and LDL receptor. J. Lipid Res. 46:1721-1731.
47. Mahley, R.W., and Huang, Y. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10:207-217.
48. Fryer, J.D., et al. 2005. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280:25754-25759.
49. Kowal, R.C., et al. 1990. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:10771-10779.
50. Narita, M., et al. 2002. Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. J. Biochem. 132:743-749.
51. Sagare, A., et al. 2007. Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med. 13:1029-1031.
52. Strittmatter, W.J., et al. 1993. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 90:1977-1981.
53. LaDu, M.J., et al. 1995. Purif ication of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 270:9039-9042.
54. Tokuda, T., et al. 2000. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 348:359-365.
55. Wyss-Coray, T., et al. 2003. Adult mouse astrocyte degrade amyloid-β in vitro and in situ. Nat. Med. 9:453-457.
56. Koistinaho, M., et al. 2004. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat. Med. 10:719-726.
57. Cole, G.M., and Ard, M.D. 2000. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta protein. Microsc. Res. Tech. 50:316-324.
58. Cirrito, J.R., et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23:8844-8853.
59. Wilhelmus, M.M.M., et al. 2005. Apolipoprotein E genotype regulates amyloid-β cytotoxicity. J. Neurosci. 25:3621-3627.
60. Hatters, D.M., Zhong, N., Rutenber, E., and Weisgraber, K.H. 2006. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J. Mol. Biol. 361:932-944.
61. Ye, S., et al. 2005. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 102:18700- 18705.
62. Sadowski, M.J., et al. 2006. Blocking the apolipoprotein E/amyloid-β interaction as potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103:18787-18792.
63. Mahley, R.W., Weisgraber, K.H., and Huang, Y. 2006. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103:5644-5651.
64. Cedazo-Mínguez, A. 2007. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 11:1227-1238.
65. 125I to high specific activity. Biochim. Biophys. Acta. 251:363-366.
66. LaRue, B., et al. 2004. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-β peptide in wild type and Alzheimer's Tg2576 mice. J. Neurosci. Methods. 138:233-242.
67. Wu, Z., Hofman, F.M., and Zlokovic, B.V. 2003. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J. Neurosci. Methods. 130:53-63.